Search

Objective To investigate the effect of immune killer cells therapy on CD4+CD25+CD127LOW and CD8+CD28-regulatory T cells in the patients with malignant tumor. Methods Fifty patients with malignant tumor treated by the immune killer cells therapy in the oncology department of our hospital from May 2011 to April 2014 were taken as the research subjects (tumor group) and 30 individuals undergoing the healthy physical examination were selected as the control group. Flow cytometry was used to detect the peripheral blood CD4+CD25+CD127LOW and T regulatory CD4+cells with CD8+CD28-and CD8+. Results The peripheral blood CD4+CD25+CD127LOW/CD4+and CD8+CD28-/CD8+before treatment in the tumor group were 11.48%±1.44% and 19.69%±5.01%, which were significantly higher than 4.65%±0.75% and 15.35%±4.71% in the control group, the differences were statistically significant (P<0.05). The peripheral blood CD4+CD25+CD127LOW/CD4+and CD8+CD28-/CD8+after treatment in the tumor group were 5.55%±0.81% and 16.15%±4.61%, which were significantly lower than before treatment with statistical differences; but slightly higher than those in the control group without statistical differences (P>0.05). Conclusion Immune killer cells in treating malignant tumor can reduce the peripheral blood CD4+CD25+CD127LOW, CD8+CD28-regulatory T cells level, corrects the immune imbalance state and improves the immune function. [ABSTRACT FROM AUTHOR]

Objectives: To investigate CD4-CD8 and CD28 expression in T cells infiltrating the vitreous fluid in patients with proliferative diabetic retinopathy and to evaluate the relationship between the infiltrating T cells and both the activity of proliferative diabetic retinopathy and the clinical outcome. Methods: Both vitreous and peripheral blood samples were obtained simultaneously from 20 consecutive diabetic patients and analyzed by flow cytometry. Three diabetic patients were excluded because there were no viable cells in the vitreous fluid. Six nondiabetic patients requiring vitrectomy were also studied. Results: T lymphocytes were detected in all 6 diabetic patients with vitreous hemorrhage and in 6 (55%) of the 11 diabetic patients without vitreous hemorrhage, hut in none of the nondiahetic patients. The percentages of T cells (CD3+), TCD4+ (CD3+ CD4+), and TCD8+ (CD3+ (CD8+) subsets, as well as the expression of CD28, were similar in the vitreous fluid and in the peripheral blood in patients with vitreous hemorrhage. However, in patients without vitreous hemorrhage, the percentage of CD4+ CD28- T cells in the vitreous fluid was significantly higher than in the peripheral blood (33.34% [20.75%-100.00%] vs 8.45% [2.43%-56.59%]; P=.02). In addition, all of these patients showed quiescent retinopathy and their outcome was better than that of patients with vitreous hemorrhage and patients in whom intravitreous T cells were undetectable. Conclusion: T cells infiltrating the vitreous of diabetic patients without vitreous hemorrhage not only show a different pattern than in the peripheral blood hut also seem to improve the prognosis of proliferative diabetic retinopathy. Clinical Relevance: Our results provide further understanding of events involved in the autoimmune response in diabetic retinopathy and may aid in the research for new treatment approaches. [ABSTRACT FROM AUTHOR]